Exceptional Response to Single-Agent Anti-PD1 Therapy Observed in Patients with Advanced Desmoplastic Melanoma By Ogkologos - September 4, 2025 721 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SWOG S1512 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR ESMO Calls for Cancer Care Safeguards in the EU’s Health Crisis... November 11, 2025 Immunotherapy Plus Chemotherapy Helps People With Advanced Nasopharyngeal Cancer: The ASCO... April 18, 2022 Digital Breast Tomosynthesis Found to Detect Invasive Cancers At a Higher... December 8, 2020 Adding Palbociclib to Maintenance Anti-HER2 and Endocrine Therapies Improves PFS Over... February 5, 2026 Load more HOT NEWS 3 ways we’re helping teenagers and young adults with cancer Receiving a Blood Transfusion During Cancer: What to Know and What... ESMO Calls for Cardio-Oncology to Be Integrated into the EU Cardiovascular... Advancing Patient Care Through Focused Innovation
